• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

mRNA COVID-19 疫苗接种后双侧多灶性中心性浆液性视网膜病变。

Bilateral multifocal central serous retinopathy following mRNA COVID-19 vaccine.

机构信息

Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon; Beirut Eye and ENT Specialist Hospital, Beirut, Lebanon.

Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon; Beirut Eye and ENT Specialist Hospital, Beirut, Lebanon; Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, United States.

出版信息

J Fr Ophtalmol. 2022 Jun;45(6):603-607. doi: 10.1016/j.jfo.2022.02.001. Epub 2022 Apr 28.

DOI:10.1016/j.jfo.2022.02.001
PMID:35599048
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9046098/
Abstract

We present a case of acute bilateral multifocal CSCR in a young healthy Caucasian female occurring 3 days after receiving the first dose of the Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine. The true incidence of this adverse reaction might be underreported in asymptomatic unilateral or paracentral cases. We believe that the post-COVID-19 vaccination occurrence of CSCR is not a sufficient reason to withhold the second dose of the vaccine. Further studies are required to ascertain the best way to prevent and manage this complication.

摘要

我们报告了一例年轻健康的白人女性在接种辉瑞-生物科技 BNT162b2 COVID-19 mRNA 疫苗第一剂后 3 天发生双侧急性多灶性 CSCR 的病例。无症状单侧或旁中心病例中，这种不良反应的真实发生率可能被低估。我们认为 COVID-19 疫苗接种后发生 CSCR 并不是拒绝接种第二剂疫苗的充分理由。需要进一步研究以确定预防和管理这种并发症的最佳方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5cf/9046098/af5a4ec5fbff/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5cf/9046098/dc1445924a9d/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5cf/9046098/65a5a4e3b46a/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5cf/9046098/49c2245a4189/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5cf/9046098/af5a4ec5fbff/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5cf/9046098/dc1445924a9d/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5cf/9046098/65a5a4e3b46a/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5cf/9046098/49c2245a4189/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5cf/9046098/af5a4ec5fbff/gr4_lrg.jpg

相似文献

1
Bilateral multifocal central serous retinopathy following mRNA COVID-19 vaccine.mRNA COVID-19 疫苗接种后双侧多灶性中心性浆液性视网膜病变。
J Fr Ophtalmol. 2022 Jun;45(6):603-607. doi: 10.1016/j.jfo.2022.02.001. Epub 2022 Apr 28.
2
Central serous chorioretinopathy following the BNT162b2 mRNA vaccine.接受 BNT162b2 mRNA 疫苗后发生中心性浆液性脉络膜视网膜病变。
J Fr Ophtalmol. 2022 Jun;45(6):597-602. doi: 10.1016/j.jfo.2022.01.006. Epub 2022 May 13.
3
Acute Unilateral Central Serous Chorioretinopathy after Immunization with Pfizer-BioNTech COVID-19 Vaccine: A Case Report and Literature Review.辉瑞-生物科技 COVID-19 疫苗接种后急性单侧中心性浆液性脉络膜视网膜病变：病例报告及文献复习。
Semin Ophthalmol. 2022 Aug;37(6):690-698. doi: 10.1080/08820538.2022.2082255. Epub 2022 Jun 3.
4
Bilateral Relentless Placoid Chorioretinitis Following Pfizer-BioNTech COVID-19 Vaccination: Specific Antigenic Trigger or Nonspecific Immune Activation?辉瑞-生物科技 COVID-19 疫苗接种后双侧持续性盘状脉络膜视网膜炎：特定抗原触发还是非特异性免疫激活？
Ocul Immunol Inflamm. 2024 Sep;32(7):1498-1503. doi: 10.1080/09273948.2023.2239338. Epub 2023 Aug 8.
5
Central serous chorioretinopathy following Pfizer-BioNTech COVID-19 vaccine: A case report.辉瑞-生物科技公司新冠疫苗接种后发生的中心性浆液性脉络膜视网膜病变：一例报告。
J Fr Ophtalmol. 2022 Jan;45(1):e1-e2. doi: 10.1016/j.jfo.2021.11.003. Epub 2021 Dec 10.
6
Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine.接种 BNT163b2（辉瑞-生物科技）mRNA COVID-19 疫苗后出现似红糠疹样疹发。
Clin Exp Dermatol. 2022 Jan;47(1):188-190. doi: 10.1111/ced.14878. Epub 2021 Sep 24.
7
Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination.分析接种 COVID-19 疫苗的类型和不良反应。
JAMA Netw Open. 2021 Dec 1;4(12):e2140364. doi: 10.1001/jamanetworkopen.2021.40364.
8
Multiple sites of thrombosis without thrombocytopenia after a second dose of Pfizer-BioNTech COVID-19 vaccine.第二剂辉瑞-BioNTech COVID-19 疫苗接种后出现无血小板减少症的多处血栓形成。
Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221128534. doi: 10.1177/03946320221128534.
9
Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.辉瑞-生物技术公司（Pfizer-BioNTech）疫苗 BNT162b2 对预防 12-17 岁青少年感染 SARS-CoV-2 的疫苗有效性的临时估计-亚利桑那州，2021 年 7 月至 12 月。
MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1761-1765. doi: 10.15585/mmwr.mm705152a2.
10
Ventricular tachycardia from myocarditis following COVID-19 vaccination with tozinameran (BNT162b2, Pfizer-BioNTech).辉瑞-生物科技 COVID-19 疫苗（BNT162b2，即 托珠单抗）接种后心肌炎引起的室性心动过速。
Pacing Clin Electrophysiol. 2022 Sep;45(9):1097-1100. doi: 10.1111/pace.14486. Epub 2022 Apr 4.

引用本文的文献

1
Ocular posterior segment complications following COVID-19 vaccination.接种 COVID-19 疫苗后的眼部后节并发症。
Int Ophthalmol. 2023 Nov;43(11):4343-4357. doi: 10.1007/s10792-023-02795-y. Epub 2023 Jul 11.
2
Central serous chorioretinopathy: Pathophysiology, systemic associations, and a novel etiological classification.中心性浆液性脉络膜视网膜病变：病理生理学、全身关联及一种新的病因分类
Taiwan J Ophthalmol. 2022 Dec 5;12(4):381-393. doi: 10.4103/2211-5056.362601. eCollection 2022 Oct-Dec.

本文引用的文献

1
Central serous chorioretinopathy following Pfizer-BioNTech COVID-19 vaccine: A case report.辉瑞-生物科技公司新冠疫苗接种后发生的中心性浆液性脉络膜视网膜病变：一例报告。
J Fr Ophtalmol. 2022 Jan;45(1):e1-e2. doi: 10.1016/j.jfo.2021.11.003. Epub 2021 Dec 10.
2
Acute corneal endothelial graft rejection following COVID-19 vaccination.新型冠状病毒肺炎疫苗接种后急性角膜内皮移植排斥反应
J Fr Ophtalmol. 2021 Oct;44(8):e445-e447. doi: 10.1016/j.jfo.2021.06.001. Epub 2021 Jul 8.
3
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
mRNA COVID-19 疫苗接种后出现心肌炎报告：免疫实践咨询委员会更新-美国，2021 年 6 月。
MMWR Morb Mortal Wkly Rep. 2021 Jul 9;70(27):977-982. doi: 10.15585/mmwr.mm7027e2.
4
Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination.mRNA COVID-19 疫苗接种后发生急性心肌炎的患者。
JAMA Cardiol. 2021 Oct 1;6(10):1196-1201. doi: 10.1001/jamacardio.2021.2828.
5
Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine.接种新冠病毒mRNA疫苗后急性发作的中心性浆液性视网膜病变
Am J Ophthalmol Case Rep. 2021 Sep;23:101136. doi: 10.1016/j.ajoc.2021.101136. Epub 2021 Jun 12.
6
Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination.7 名青少年在接种辉瑞-BioNTech COVID-19 疫苗后出现症状性急性心肌炎。
Pediatrics. 2021 Sep;148(3). doi: 10.1542/peds.2021-052478. Epub 2021 Jun 4.
7
Different hydration states and passive tumor targeting ability of polyethylene glycol-modified dendrimers with high and low PEG density.具有高和低 PEG 密度的聚乙二醇修饰树状大分子的不同水合状态和被动肿瘤靶向能力。
Mater Sci Eng C Mater Biol Appl. 2021 Jul;126:112159. doi: 10.1016/j.msec.2021.112159. Epub 2021 May 1.
8
Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.免疫分析鼠抗 CD3 诱导的细胞因子释放综合征模型和抗细胞因子抗体的治疗效果。
Eur J Immunol. 2021 Aug;51(8):2074-2085. doi: 10.1002/eji.202149181. Epub 2021 May 19.
9
Review the safety of Covid-19 mRNA vaccines: a review.新冠病毒信使核糖核酸疫苗安全性综述：一篇综述
Patient Saf Surg. 2021 May 1;15(1):20. doi: 10.1186/s13037-021-00291-9.
10
COVID-19 and Eye: A Review of Ophthalmic Manifestations of COVID-19.COVID-19 与眼睛：COVID-19 眼部表现的综述。
Indian J Ophthalmol. 2021 Mar;69(3):488-509. doi: 10.4103/ijo.IJO_297_21.